- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaTu, Sanfang; Zhou, Lijuan; Huang, Rui; Zhou, Xuan; Yang, Jilong; Li, Meifang; Jin, Bo; Wang, Langqi; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in AdultsTu, Sanfang; Zhou, Lijuan; Huang, Rui; Zhou, Xuan; Yang, Jilong; Li, Meifang; Jin, Bo; Wang, Langqi; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)Xiao, Yi; Wu, Jiaying; Zhou, Mi; Shang, Zhen; Zhu, Ming65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
20阅读
